Vizsgálati helyszín
Chicago
Chicago, Illinois 60637, Egyesült ÁllamokMég nincs intézményhez kötve
- 17futó vizsgálat
- 7lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 24 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis12 vizsgálat
- 2. fázis6 vizsgálat
- 1. fázis3 vizsgálat
- 1/2. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz10 vizsgálat
- Lezárult7 vizsgálat
- Toboroz7 vizsgálat
- Fő szponzor
- GlaxoSmithKline12 vizsgálat
- ViiV Healthcare9 vizsgálat
- Tesaro, Inc.3 vizsgálat
Futó vizsgálatok
Toboroz
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
NCT07805707· 3. fázis· GlaxoSmithKline· Forrás
Contact: Dennis Levinson (principal investigator)
Toboroz
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916· 3. fázis· ViiV Healthcare· Forrás
Contact: Mariam Aziz (principal investigator)
Toboroz
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546· 2. fázis· ViiV Healthcare· Forrás
Contact: Aniruddha Hazra (principal investigator)
Fut, nem toboroz
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
NCT07053384· 1. fázis· ViiV Healthcare· Forrás
Toboroz
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06961214· 3. fázis· GlaxoSmithKline· Forrás
Contact: Thomas Wade (principal investigator)
Toboroz
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095· 3. fázis· GlaxoSmithKline· Forrás
Contact: Daniel Meza (principal investigator)
Fut, nem toboroz
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
NCT06741397· 2. fázis· ViiV Healthcare· Forrás
Fut, nem toboroz
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805· 3. fázis· ViiV Healthcare· Forrás
Toboroz
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717· 2/3. fázis· GlaxoSmithKline· Forrás
Contact: Bradford Bemiss (principal investigator)
Fut, nem toboroz
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
NCT05996471· 2. fázis· ViiV Healthcare· Forrás
Toboroz
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· 3. fázis· GlaxoSmithKline· Forrás
Contact: Al Benson Iii (principal investigator)
Fut, nem toboroz
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
NCT03299049· 3. fázis· ViiV Healthcare· Forrás
Fut, nem toboroz
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
NCT02951052· 3. fázis· ViiV Healthcare· Forrás
Fut, nem toboroz
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633· 1. fázis· Tesaro, Inc.· Forrás
Fut, nem toboroz
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284· 1. fázis· Tesaro, Inc.· Forrás
Fut, nem toboroz
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
NCT02362503· 3. fázis· ViiV Healthcare· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek